Brokerages Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) PT at $87.38

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been given an average recommendation of “Moderate Buy” by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $87.3750.

KNSA has been the topic of several research analyst reports. Wedbush lifted their price objective on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Citigroup upped their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Weiss Ratings cut Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, August 13th. The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, Canaccord Genuity Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, Director G. Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the sale, the director owned 11,672 shares of the company’s stock, valued at $950,450.96. The trade was a 23.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Michael R. Megna sold 4,600 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the sale, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after acquiring an additional 49,802 shares in the last quarter. UBS Group AG lifted its stake in Kiniksa Pharmaceuticals International by 56.4% in the 4th quarter. UBS Group AG now owns 77,916 shares of the company’s stock valued at $3,214,000 after purchasing an additional 28,099 shares during the last quarter. Inspire Investing LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $1,698,000. BNP Paribas Financial Markets lifted its position in shares of Kiniksa Pharmaceuticals International by 27.3% during the 4th quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock valued at $34,311,000 after acquiring an additional 178,366 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Kiniksa Pharmaceuticals International by 18.2% in the first quarter. SG Americas Securities LLC now owns 640,179 shares of the company’s stock worth $30,825,000 after purchasing an additional 98,783 shares during the period. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Trading Down 3.2%

Shares of NASDAQ KNSA opened at $77.91 on Monday. Kiniksa Pharmaceuticals International has a 12 month low of $35.12 and a 12 month high of $82.94. The stock has a market cap of $6.08 billion, a price-to-earnings ratio of 80.32 and a beta of 0.09. The company has a 50 day simple moving average of $71.98 and a two-hundred day simple moving average of $57.36.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%.The company had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Analysts forecast that Kiniksa Pharmaceuticals International will post 1.37 EPS for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.